(Q33378539)

26 July 2017

title

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas (English)

1 reference

26 July 2017

0 references

7

Michael Sisti

1 reference

26 July 2017

5

Paul G Fisher

0 references

author name string

Casilda Balmaceda

1

1 reference

26 July 2017

David Peereboom

2

1 reference

26 July 2017

Susan Pannullo

3

1 reference

26 July 2017

Ying Kuen K Cheung

4

1 reference

26 July 2017

Paul G Fisher

5

1 reference

26 July 2017

Jane Alavi

6

1 reference

26 July 2017

Johnson Chen

8

1 reference

26 July 2017

Robert L Fine

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

112

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1139-1146

1 reference

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

Temozolomide chemotherapy in recurrent oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

The Charing Cross Hospital experience with temozolomide in patients with gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

An Australian experience with temozolomide for the treatment of recurrent high grade gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23167

7 January 2021

Identifiers

DOI

10.1002/CNCR.23167

1 reference

26 July 2017

1 reference